In light of the significant drop in Regeneron’s stock price, a natural question emerges: is REGN now a viable buying ...

The stock’s decline was notably more severe than that of its partner, Sanofi (NASDAQ:SNY), which experienced a 6% drop. Bernstein SocGen analysts highlighted concerns about Regeneron’s ability ...

The decision follows recent challenges faced by the company, including the failure of itepekimab and ongoing issues ... stock decline, but analysts still see long-term value in Regeneron’s ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $300.0 to $600.0 for Regeneron Pharmaceuticals over the last 3 months ...

Regeneron Pharmaceuticals (NasdaqGS:REGN) announced favorable Phase 3 trial results for itepekimab and entered a significant licensing agreement with Telesis Bio, enhancing its R&D capabilities.

could shift investor focus away from concerns over the erosion of Eylea, another of Regeneron’s products. This shift could potentially lead to an appreciation in stock value, aligning it more closely ...

They encourage investors to remain buyers of Regeneron’s stock, anticipating a meaningful appreciation in value as the market shifts its focus towards the company’s broader portfolio and future growth ...

Amgen Q1 2025 results beat estimates with strong product growth. Stay updated on tariff risks and drug pricing impacts.

The S&P 500 slipped 0.4% on Tuesday, May 20, snapping a six-day winning streak as investors' confidence on trade and ...

Regeneron's stock was up just over 1%. The steep discount on the once highly valued testing firm puts an end to concerns about the ... testing model still holds value. That has been evidenced ...

“We think itepekimab’s disappointing data create a big challenge for REGN in the long ... he believes “the valuation is already reflective of the risks, yet the stock lacks upside catalysts ...